Kaplan J E
Adv Shock Res. 1982;7:159-72.
Previous studies have suggested that plasma fibronectin is a component of the physiological antithrombotic mechanism and is related to resistance to cardiopulmonary failure during sepsis. The current study addresses the hypothesis that fibronectin deficiency results in increased sensitivity to thrombosis during sepsis, whereas increased fibronectin results in enhanced resistance. Rats were injected with purified fibronectin, antiserum to fibronectin, antiserum to albumin or vehicle prior to intraaortic infusion of saline, live Escherichia coli (10(7)--10(8)/100 gm) or E coli endotoxin (0.001--0.1 mg/100 gm). Infusion of the higher doses was associated with greater mortality in antifibronectin groups than the other groups. Mean arterial blood pressure fell transiently in all groups following injection of antifibronectin but not following the other pretreatment. Both endotoxin and bacterial infusion resulted in severe thrombocytopenia in antifibronectin-treated animals and to a lesser extent following antialbumin. Fibrinogen consumption was increased in all groups after antifibronectin treatment in bacteria infused animals after pretreatment with antialbumin or fibronectin. Fibrin degradation products were increased by bacterial infusion in animals treated with either antiserum. The current data support a relationship between plasma fibronectin and resistance to thrombosis. The relationship was not as clear-cut as that previously observed for nonseptic thrombotic states.
先前的研究表明，血浆纤连蛋白是生理性抗血栓形成机制的一个组成部分，并且与脓毒症期间对心肺功能衰竭的抵抗力有关。当前的研究探讨了这样一种假说，即纤连蛋白缺乏会导致脓毒症期间对血栓形成的敏感性增加，而纤连蛋白增加则会导致抵抗力增强。在向大鼠主动脉内输注生理盐水、活的大肠杆菌（10⁷ - 10⁸ / 100克）或大肠杆菌内毒素（0.001 - 0.1毫克/ 100克）之前，给大鼠注射纯化的纤连蛋白、抗纤连蛋白抗血清、抗白蛋白抗血清或赋形剂。与其他组相比，抗纤连蛋白组中较高剂量的输注与更高的死亡率相关。注射抗纤连蛋白后，所有组的平均动脉血压均短暂下降，但在其他预处理后未出现这种情况。内毒素和细菌输注均导致抗纤连蛋白处理的动物出现严重血小板减少，抗白蛋白处理后程度较轻。在用抗白蛋白或纤连蛋白预处理后，在输注细菌的动物中，抗纤连蛋白处理后所有组的纤维蛋白原消耗均增加。在用任一抗血清处理的动物中，细菌输注都会增加纤维蛋白降解产物。当前的数据支持血浆纤连蛋白与抗血栓形成之间的关系。这种关系不像先前在非脓毒症血栓形成状态中观察到的那样明确。
